Lonnie Moulder Email Address

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates| and to commercialize safer and more effective products for the treatment and support of cancer patients. Since its founding, TESARO has made substantial progress toward building a leading oncology-focused pipeline. In December 2010, the Company announced that it had in-licensed its first product, rolapitant, from OPKO Health, Inc. Rolapitant is a Phase 3-ready neurokinin-1 (NK1) receptor antagonist being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). In March 2011, TESARO announced that it had in-licensed small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK) from Amgen Inc. that have promising potency, selectivity and pharmaceutical properties. The ALK program represents a molecularly targeted approach to treating certain cancer sub-populations. TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein| recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline. In May 2010, NEA and TESARO management funded an initial $20 million Series A financing to facilitate the Company's acquisition, development and commercialization of a portfolio of oncology and supportive care products. In June 2011, TESARO announced that it secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio. Participants included founding investor New Enterprise Associates (NEA) and new investors: InterWest Partners, Kleiner Perkins Caufield & Byers (KPCB), Venrock, Pappas Ventures, T. Rowe Price, Oracle Partners, Deerfield Management and Leerink Swann. NEA is the largest investor in the Series B financing. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.